New cocktail aims to stamp out ovarian cancer leftovers
NCT ID NCT06083844
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This study tests whether a combination of three drugs—pembrolizumab, bevacizumab, and low-dose cyclophosphamide—can help control high-grade ovarian cancer that still has small amounts of disease after initial therapy. About 20 women aged 18 and older with this type of ovarian cancer will participate. The main goal is to see if the treatment is safe and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.